Trials / Completed
CompletedNCT02195869
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease
A Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Pharmacyclics LLC. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and clinical efficacy of ibrutinib in subjects with steroid dependent or refractory Chronic Graft Versus Host Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ibrutinib |
Timeline
- Start date
- 2014-07-14
- Primary completion
- 2017-09-15
- Completion
- 2017-09-15
- First posted
- 2014-07-21
- Last updated
- 2019-07-11
- Results posted
- 2019-07-11
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02195869. Inclusion in this directory is not an endorsement.